Furthermore, we demonstrate itspotential utility for managing BTZ-resistant and aggressive MM tumors.In an in vitro model of BTZ-resistant MM, we demonstratedthat while the IC50 of BTZ-F was 188 nM, the IC50 of ATBL was 3-foldlower (∼80 nM), suggesting greater efficacy of ATBL even inthe context of resistant tumors. Here, CASC3 is linked to Miyoshi myopathy.